Please login to the form below

Not currently logged in
Email:
Password:

Zevtera

This page shows the latest Zevtera news and features for those working in and with pharma, biotech and healthcare.

Basilea moves closer to US filing of novel antibiotic

Basilea moves closer to US filing of novel antibiotic

Ceftobiprole is already marketed as  Zevtera and Mabelio for hospital and community-acquired pneumonia (HAP and CAP) in Europe and other ex-US markets through multiple partner companies.

Latest news

  • Basilea bags $72m upfront from Pfizer for antifungal license Basilea bags $72m upfront from Pfizer for antifungal license

    Basilea launched the antifungal in its first European markets last year - Austria, France, Germany, Italy and the UK - with combined sales of the antifungal and new antibiotic Zevtera (ceftobiprole) reaching ... Meanwhile, Basilea says it is still on the

  • Basilea’s novel antibiotic reaches UK market Basilea’s novel antibiotic reaches UK market

    Swiss biopharma company Basilea has launched its new cephalosporin antibiotic Zevtera in the UK, the latest market in its European roll-out for the drug. . ... The launch of Zevtera in Europe is being supported by Quintiles' commercial services unit

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Basilea appoints commercial head Basilea appoints commercial head

    Ronald Scott, CEO of Basilea, commented that Veitch's “extensive experience and in-depth knowledge of European pharmaceutical markets will be instrumental” as the company prepares to launch its antibiotic Zevtera

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics